XILING LAB CO.,LTD
About XILING LAB CO.,LTD
Certifications
-
FDA -
GMP
Categories
-
Country/Region:China
-
On CPHI since:2017
-
Certificates:2
-
Employees:50 - 99
Company types
Primary activities
Products from XILING LAB CO.,LTD (3)
-
Product Eribulin Mesylate (API)
Generic Name: Eribulin Mesylate Injection
Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
Liposarcoma (US, EU)
Soft tissue sarcoma (Japan and other countries)
Guidelines:
NCCN （2023V4）， CSCO （2023）， ESMO （2023） ... -
Product Eribulin Mesylate Injection
Generic Name: Eribulin Mesylate Injection
Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
Liposarcoma (US, EU)
Soft tissue sarcoma (Japan and other countries)
Guidelines:
NCCN （2023V4）， CSCO （2023）， ESMO （2023）
Exc... -
Product Lurbinectedin (API)
Generic Name: Lurbinectedin lyophilized powder
Indication: Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Originator: Pharma Mar
Approval: US: June. 2020 &nbs...
XILING LAB CO.,LTD Resources (1)
-
Brochure Brochure-Xiling Lab's Product List
Xiling Lab covers full chain of pharmaceutical industry with strong background and robust capabilities. We specialize in innovative XDC platform technology (especially linker-drug systems and conjugation technology) and highly complex generic products. I am writing to seek potential opportunity of becoming your supplier (both for development and commercial stage) of our excellent oncology APIs, including Lurbinectedin, Eribulin Mesylate and Trabectedin. Please kindly find our brochure for more information.